Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling

References

• Ma J, Jemal A. Breast Cancer Statistics Breast Cancer Metastasis and Drug Resistance. New York: Springer; 2013; 1-18
   Google Scholar
• Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004; 51:55-67; PMID:15207254; http://dx.doi.org/10.1016/j.critrevonc.2004.02.001
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. New Engl J Med 2006; 354:270-82; http://dx.doi.org/10.1056/NEJMra050776
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7:4338s-42s; PMID:11916222
   PubMed Web of Science ®Google Scholar
• Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29:2905-19; PMID:11452016; http://dx.doi.org/10.1093/nar/29.14.2905
   PubMed Web of Science ®Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005; 123:21-7; PMID:15762276; http://dx.doi.org/10.1309/4WV79-N2GHJ3X1841
   PubMed Web of Science ®Google Scholar
• Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 2006; 6:360-8; PMID:16633364; http://dx.doi.org/10.1038/nrc1879
   PubMed Web of Science ®Google Scholar
• Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol 2013; 75:225-40; PMID:23043248; http://dx.doi.org/10.1146/annurev-physiol-030212-183708
   PubMed Web of Science ®Google Scholar
• Caldon CE, Sutherland RL, Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 2010; 9:1918-28; PMID:20473028; http://dx.doi.org/10.4161/cc.9.10.11474
   PubMed Web of Science ®Google Scholar
• Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr-Relat Cancer 2005; 12 (Suppl 1):S47-59; PMID:16113099
   PubMedGoogle Scholar
• Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostène W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000; 65:593-8; PMID:11108864; http://dx.doi.org/10.1016/S0039-128X(00)00172-0
   PubMed Web of Science ®Google Scholar
• Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN. Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 2004; 75:3157-71; PMID:15488895; http://dx.doi.org/10.1016/j.lfs.2004.06.010
   PubMed Web of Science ®Google Scholar
• Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007; 27:133-48; PMID:16888751; http://dx.doi.org/10.1002/med.20077
   PubMed Web of Science ®Google Scholar
• Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000; 49:355-61; PMID:10996033; http://dx.doi.org/10.1016/S0162-3109(00)00256-3
   PubMed Web of Science ®Google Scholar
• Hur JM, Shim JS, Jung HJ, Kwon HJ. Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin vitro. Exp Mol Med 2005; 37:133-7; PMID:15886527; http://dx.doi.org/10.1038/emm.2005.18
   PubMed Web of Science ®Google Scholar
• Park EJ, Zhao YZ, Kim YC, Sohn DH. Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo. Food Chem Toxicol 2009; 47:2742-8; PMID:19695300; http://dx.doi.org/10.1016/j.fct.2009.08.007
   PubMed Web of Science ®Google Scholar
• Kim EJ, Jung SN, Son KH, Kim SR, Ha TY, Park MG, Jo IG, Park JG, Choe W, Kim SS, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol 2007; 72:62-72; PMID:17429005; http://dx.doi.org/10.1124/mol.107.034447
   PubMed Web of Science ®Google Scholar
• Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 2009; 69:193-202; PMID:19118003; http://dx.doi.org/10.1158/0008-5472.CAN-08-2575
   PubMed Web of Science ®Google Scholar
• Wu CY, Hsieh CY, Huang KE, Chang C, Kang HY. Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int J Cancer 2012; 131:1423-34; PMID:22052438; http://dx.doi.org/10.1002/ijc.27343
   PubMed Web of Science ®Google Scholar
• Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett 2012; 316:11-22; PMID:22154085; http://dx.doi.org/10.1016/j.canlet.2011.10.006
   PubMed Web of Science ®Google Scholar
• Lee WY, Liu KW, Yeung JH. Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 2009; 285:46-57; PMID:19467570; http://dx.doi.org/10.1016/j.canlet.2009.04.040
   PubMed Web of Science ®Google Scholar
• Chen W, Liu L, Luo Y, Odaka Y, Awate S, Zhou H, Shen T, Zheng S, Lu Y, Huang S. Cryptotanshinone activates p38JNK and inhibits Erk12 leading to caspase-independent cell death in tumor cells. Cancer Prev Res 2012; 5:778-87; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0551
   PubMed Web of Science ®Google Scholar
• Chen L, Zheng SZ, Sun ZG, Wang AY, Huang CH, Punchard NA, Huang SL, Gao X, Lu Y. Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity. Cancer Chemoth Pharm 2011; 68:17-27; http://dx.doi.org/10.1007/s00280-010-1440-8
   PubMed Web of Science ®Google Scholar
• Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, Shen T, Liu Z, Lu Y, Huang S. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res 2010; 3:1015-25; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0020
   PubMed Web of Science ®Google Scholar
• Park IJ, Kim MJ, Park OJ, Choe W, Kang I, Kim SS, Ha J. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis 2012; 17:248-57; PMID:22113823; http://dx.doi.org/10.1007/s10495-011-0680-3
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-72; PMID:21734724; http://dx.doi.org/10.1038/nrc3090
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, Chang KC, Kim HJ. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 2008; 33(3):485-91; PMID:18695877
   PubMed Web of Science ®Google Scholar
• Park IJ, Yang WK, Nam SH, Hong J, Yang KR, Kim J, Kim SS, Choe W, Kang I, Ha J. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis 2014; 19:615-18; PMID:24173372; http://dx.doi.org/10.1007/s10495-013-0929-0
   PubMed Web of Science ®Google Scholar
• Wang H, Wu R, Yu L, Wu F, Li S, Zhao Y, Li H, Luo G, Wang J, Zhou J. SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression. Oncol Rep 2012; 28:1468-74; PMID:22824926
   PubMed Web of Science ®Google Scholar